BeiGene Ltd. ADR (BGNE): Price and Financial Metrics
BGNE Price/Volume Stats
| Current price | $176.50 | 52-week high | $248.16 |
| Prev. close | $174.72 | 52-week low | $126.97 |
| Day low | $175.80 | Volume | 368,400 |
| Day high | $179.25 | Avg. volume | 284,893 |
| 50-day MA | $201.59 | Dividend yield | N/A |
| 200-day MA | $178.25 | Market Cap | 17.20B |
BGNE Stock Price Chart Interactive Chart >
BeiGene Ltd. ADR (BGNE) Company Bio
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019. (Source:Wikipedia)
BGNE Price Returns
| 1-mo | -9.28% |
| 3-mo | -12.62% |
| 6-mo | 10.90% |
| 1-year | 0.22% |
| 3-year | -35.56% |
| 5-year | 4.01% |
| YTD | -2.14% |
| 2023 | -18.00% |
| 2022 | -18.82% |
| 2021 | 4.85% |
| 2020 | 55.88% |
| 2019 | 18.18% |
Continue Researching BGNE
Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...